PALI – palisade bio, inc. (US:NASDAQ)
Stock Stats
News
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile [Yahoo! Finance]
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio (PALI) was upgraded by Wolfe Research to "strong-buy".
Palisade Bio (PALI) is now covered by Wolfe Research. They set an "outperform" rating and a $7.00 price target on the stock.
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Form PRE 14A PALISADE BIO, INC. For: Apr 17
Form 8-K PALISADE BIO, INC. For: Mar 27
Form 10-K PALISADE BIO, INC. For: Dec 31
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Point72 Asset Management, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.